Sparx Group Announces First Patient Dosed With SPX-303 Injection, the First in Its Class of Anti-Lilrb2/Pd-L1 Bispecific Antibody Drugs
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.